

10/551138

JC20 Rec'd PCT/PTO 29 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Dimitrios E. LIZOS et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2005_1543A
Filed September 29, 2005 :

COMPOUNDS HAVING SEROTONIN 5-HT₁₇
RECEPTOR ANTAGONIST ACTIVITY AND
MUSCARINIC M₄ RECEPTOR AGONIST
ACTIVITY AND THEIR USE IN THE
TREATMENT OF PSYCHOTIC DISORDERS
[Corresponding to PCT/GB2004/001367
Filed March 29, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application
PCT/GB2004/001367; and/or
- ☐ each reference previously cited in prior parent application Serial No.
_____.

1a. ☒ This Information Disclosure Statement is submitted:

ATTACHMENT C }

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification

JC20 Rec'd P&T/PTO 29 SEP 2005


after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Dimitrios E. LIZOS et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 29, 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 29, 2005

ATTY DOCKET NO.
2005_1543ASERIAL NO.
NEW**10/551138**APPLICANT
Dimitrios E. LIZOS et al.FILING DATE
September 29, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,539,631	11/1970	Pallos et al.			
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	99/04778	2/1999	WO			
	AD	96/29316	9/1996	WO			
	AE	0 011 182	5/1980	EP			X
	AF						
	AG						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Database Registry, Chemical Abstracts Service, April 12, 1986, Chemical Abstracts: RN 101398-76-9, XP002287521, Abstract.
	AI	Frank P. Bymaster et al., "Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane", European Journal of Pharmacology, Vol. 356, No. 2-3, September 4, 1998, pp. 109-119.
	AJ	S. M. Cochran et al., "Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol", Neuropharmacology, Vol. 43, No. 3, September 2002, pp. 394-407.
	AK	B. Pouzet et al., "Effects of the 5-HT ₂ receptor antagonist SB-258741 in animal models for schizophrenia", Pharmacology, Biochemistry and Behavior, Vol. 71, No. 4, April 2002, pp. 655-665.
	AL	
	AM	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.